Overview

Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This phase II open-label study will be performed to evaluate the response rate of brain metastases from lung and breast tumors under treatment with WBRT and lapatinib.
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Cooperative Oncology Group
Treatments:
Lapatinib